The ambitious experiment to integrate software into the pharmacy bag is facing a reckoning. Germany’s statutory health insurance providers are now calling for a fundamental overhaul of how Gesundheits-Apps auf Rezept—prescription health apps—are priced and validated, citing a systemic lack of evidence for the benefits some of these tools provide.
A recent report reveals a widening gap between the financial investment in digital therapeutics and the clinical proof of their efficacy. Since the introduction of the “fast-track” prescription model in 2020, statutory health insurance (GKV) funds have spent approximately 400 million euros on these digital interventions. While the initiative was designed to modernize patient care, the GKV now argues that the current framework allows manufacturers to set prices without sufficient initial proof of utility.
The scale of the rollout has been significant, with these apps being prescribed roughly 1.6 million times. However, the sustainability of the program is under scrutiny as the regulatory body begins to prune the list of approved applications to ensure only those with demonstrated value remain accessible to patients.
The Attrition of Digital Therapeutics
The lifecycle of these apps—officially known as Digitale Gesundheitsanwendungen (DiGA)—has proven volatile. According to the latest figures, 74 apps were initially admitted into the official directory. However, the rigorous follow-up requirements for proving “positive care effects” have led to the removal of 16 applications. By the end of 2025, only 58 apps remained in the official performance catalog.
This attrition highlights the difficulty manufacturers face in transitioning from a “promising” prototype to a clinically validated medical tool. The Federal Institute for Drugs and Medical Devices (BfArM), which serves as the auditing body, requires that apps provide evidence of their benefit within a specific timeframe after their initial provisional listing. When the data fails to meet these benchmarks, the apps are stripped of their prescription status.
| Metric | Value |
|---|---|
| Total Apps Initially Listed | 74 |
| Apps Removed from Directory | 16 |
| Apps Remaining (End of 2025) | 58 |
| Total Prescriptions Issued | ~1.6 Million |
| Total GKV Expenditure | ~400 Million Euros |
A ‘Structural Problem’ in Pricing
Beyond the clinical evidence, the GKV has identified a “structural” flaw in the legislative framework governing the costs of Gesundheits-Apps auf Rezept. Under current rules, manufacturers are permitted to set the price of their application at any level they choose during the first year of listing.
This pricing freedom was originally intended to incentivize innovation and allow startups to recoup development costs. However, the GKV contends that this has created a financial loophole where the public health system bears the risk of paying premium prices for tools that may not ultimately deliver the promised health outcomes. The insurers are now demanding a correction to this mechanism, insisting that a proof of benefit be required from the extremely beginning of the reimbursement period, rather than as a retrospective requirement.
Who Is Affected by These Changes?
The push for stricter evidence and pricing controls creates a ripple effect across the healthcare ecosystem:
- Patients: Those using apps that are removed from the directory may lose insurance coverage for their digital therapy, potentially interrupting treatment for chronic conditions or mental health issues.
- Developers: Smaller health-tech firms may struggle to survive if the “first-year” pricing freedom is revoked, as they rely on that initial revenue to fund the expensive clinical trials required for permanent listing.
- Physicians: Doctors who prescribe these tools face increasing uncertainty about which apps will remain covered by insurance, complicating long-term treatment plans.
The Role of the BfArM and Future Oversight
The Federal Ministry of Health and the BfArM remain the central pillars of this process. The BfArM’s role is not merely administrative; it is a scientific gatekeeper. The current tension stems from the “fast-track” philosophy, which prioritizes rapid access to digital tools over the traditional, slower pace of medical device certification.
The GKV’s demand for “benefit proof from the start” suggests a shift in philosophy: moving away from a “test-and-learn” approach toward a more traditional medical evidence model. This shift aims to protect the solvency of the statutory health insurance system while ensuring that digitalization in healthcare is driven by patient outcomes rather than software marketing.
Disclaimer: This article is for informational purposes only and does not constitute medical or financial advice. Please consult a healthcare provider or insurance representative regarding specific prescription apps.
The next critical checkpoint will be the legislative review of the DiGA pricing model, where policymakers must decide whether to maintain the current incentive structure for innovators or adopt the GKV’s demand for immediate evidence of utility. Official updates on directory changes are typically published via the BfArM’s public registry.
Do you use a prescription health app? We invite you to share your experience in the comments or share this article with others navigating digital health.
